Astrazeneca (AZN) said Monday its phase 3b trial of Airsupra asthma rescue therapy showcased statistically meaningful improvements across primary and secondary endpoints in patients with mild asthma compared with albuterol medicine.
The primary efficacy endpoint was the time to first severe asthma exacerbation during the trial. Secondary endpoints involved severe exacerbation rate and usage of total systemic corticosteroids. The trial revealed that Airsupra markedly lowered the risk of a severe exacerbation by 47% compared with albuterol, the company said.
Regarding secondary endpoints, patients on Airsupra had 63% lower exposure to total systemic corticosteroids during treatment versus albuterol alone, reducing risks from cumulative exposure to SCS. Comparable reductions across primary and secondary endpoints were also observed in a prespecified subgroup of adult patients, according to the company.
The trial results show that Airsupra's safety and tolerability were consistent with its safety profile, recording no clinically meaningful changes in safety results between the Airsupra and albuterol groups, according to a statement.
Trial results were presented at the American Thoracic Society 2025 International Conference in San Francisco.
Shares were up nearly 1% in recent trading.
Price: 69.51, Change: +0.70, Percent Change: +1.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.